A real weight loss drug, called retatrutide, is currently being developed by pharmaceutical giant Eli Lilly, but there has ...
In September 2024, Sanofi entered an exclusive licensing agreement with Orano Med and RadioMedix to globally commercialize ...
Obesity has long been known as a risk factor for a host of diseases like cancer and dementia, but researchers now say that ...
212Pb-DOTAMTATE showed significant antitumor activity in PRRT-exposed GEP-NETs, with a 34.6% objective response rate and 96.2% disease control rate. The 18-month progression-free survival and overall ...